Technical analyst Clive Maund reviews the 1-year chart for Reliq Health Technologies to tell you whether he believes it is a Buy.
We caught a perfect buy spot when we went for Market Notebook update), as right after, it proceeded to break out of a quite large Head-and-Shoulders bottom to rise quite steeply.at the start of the month (it was recommended in a
This resulted in good percentage gains for us in a short space of time.
The purpose of this update is to point out that it still looks good here and, in fact, is at another buy spot as it is starting to break out of a completing bull Flag that has formed over the past couple of weeks, as we can see on its latest 1-year chart below.
Yesterday would have been the perfect time to buy, of course, because it ended up adding $0.04 by the end of the day, but it still looks good here, as a breakout from the Flag should lead to a rally of similar magnitude to the one preceding the Flag.
We, therefore, stay long, and this is a good point to add to positions or make fresh purchases. Reliq trades in reasonable volumes on the US OTC market.
Reliq Health Tech closed at CA$0.71, $0.54 on November 21, 2022.
|Want to be the first to know about interesting Life Sciences Tools & Diagnostics and Technology investment ideas? Sign up to receive the FREE Streetwise Reports’ newsletter.||Subscribe|
The above represents the opinion and analysis of Mr. Maund, based on data available to him, at the time of writing. Mr. Maund’s opinions are his own, and are not a recommendation or an offer to buy or sell securities. Mr. Maund is an independent analyst who receives no compensation of any kind from any groups, individuals or corporations mentioned in his reports. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund’s opinions on the market and stocks can only be construed as a solicitation to buy and sell securities when they are subject to the prior approval and endorsement of a Registered Securities Advisor operating in accordance with the appropriate regulations in your area of jurisdiction.
1) Clive Maund: I, or members of my immediate household or family, own securities of the following companies mentioned in this article: None. I personally am, or members of my immediate household or family are, paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Reliq Health Technologies Inc. Click here for important disclosures about sponsor fees.
3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Reliq Health Technologies Inc., a company mentioned in this article.